The Sanyal Phase 2a in MASLD examined 98 adults with metabolic dysfunction-associated steatotic liver disease and 10 percent liver fat content, randomised to retatrutide or placebo over 48 weeks
Baldassarre MPA, Di Dalmazi G, Coluzzi S, Carrieri F, Febo F, Centorame G et al
( PMID: 31389984 ) Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang DM, Park HS, Pichler W, Sanchez-Borges M, Shiohara T, Thong BY (2014) International consensus on drug allergy
Compounded semaglutide undergoes the same quality testing and purity verification as branded versions, with the key difference being cost and direct accessibility without insurance intermediaries
This is especially important for individuals with type 2 diabetes, where the body's ability to respond to insulin is compromised
Rosenstock J., Reusch, J., Bush, M., Yang, F